# Effect of Sulodexide in Early Diabetic Nephropathy

> **NCT00130208** · PHASE3 · COMPLETED · sponsor: **Keryx Biopharmaceuticals** · enrollment: 1056 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** Sulodexide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00130208
- **Lead sponsor:** Keryx Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-01
- **Final completion:** 2008-02
- **Target enrollment:** 1056 (ACTUAL)
- **Last updated:** 2018-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130208, "Effect of Sulodexide in Early Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00130208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*